Related Experiment Videos
Inflammatory and Genetic Determinants of Functional Status in HFpEF: The Role of Circulating IL-6 and IL6
Neda Ćićarić1,2, Sanja Matić3, Natasa Djordjevic2
1Clinic for Cardiology, University Clinical Center Kragujevac, 34000 Kragujevac, Serbia.
Abstract:
Background/Objectives: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome characterized by systemic inflammation and impaired functional capacity. Interleukin-6 (IL-6) is implicated in HFpEF pathophysiology, but the influence of IL6 genetic variability on its clinical impact remains unclear. This study investigated the associations of circulating IL-6, IL6 polymorphisms, and functional severity in HFpEF. Methods: This single-center observational study included 110 clinically stable HFpEF patients. Clinical, laboratory, and functional data, including C-reactive protein (CRP), IL-6 serum levels were collected. The neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio were calculated from complete blood count, while IL6 polymorphisms rs1800795 and rs1818879 were genotyped using TaqMan assays. Functional status was assessed using NYHA classification, the six-minute walk test (6MWT), and the Borg dyspnea scale. Results: Among carriers of the rs1800795 G/C+C/C genotype, elevated IL-6 was associated with higher odds of advanced symptoms (NYHA III; OR = 6.08, 95% CI 1.45-25.45, p = 0.014) and reduced exercise capacity (6MWT; OR = 6.55, 95% CI 1.60-26.72, p = 0.009). The combined effect of elevated IL-6 levels and the rs1800795 genotype was also associated with greater dyspnea burden, as assessed by the Borg scale (OR = 1.17, 95% CI 1.02-1.34, p = 0.029). In multivariable analysis, the NYHA and 6MWT models additionally retained NLR as an independent predictor, while the Borg model included advanced age, pulmonary hypertension, and the combined effect of elevated IL-6 levels and the rs1800795 genotype. Conclusions: The observed combined effect of elevated IL-6 levels and the rs1800795 genotype on symptom burden and functional impairment suggests that combined inflammatory and genetic profiling may improve severity assessment in HFpEF.
Related Concept Videos
Pathophysiology of Heart Failure
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Heart Failure I: Introduction
Heart Failure II: Pathophysiology
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Heart Failure IV: Classification and Diagnostic Evaluation